Imperial College London
Portrait Picture

DrRashaAl-Lamee

Faculty of Medicine, National Heart & Lung Institute

Clinical Reader in Cardiovascular Science
 
 
 
//

Contact

 

r.al-lamee13

 
 
//

Location

 

Block B Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Hartley:2021:10.3389/fcvm.2021.757030,
author = {Hartley, A and Khamis, R and Al-Lamee, R and Shun-Shin, M and Haskard, D and Francis, D},
doi = {10.3389/fcvm.2021.757030},
journal = {Frontiers in Cardiovascular Medicine},
title = {The placebo-controlled effect of percutaneous coronary intervention on exercise induced changes in anti- malondialdehyde-LDL antibody levels in stable coronary artery disease: a substudy of the ORBITA Trial},
url = {http://dx.doi.org/10.3389/fcvm.2021.757030},
volume = {8},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Aim: Malondialdehyde-modified low-density lipoprotein (MDA-LDL) forms a significantcomponent of oxidized LDL. The effects of exercise on levels of MDA-LDL and antiMDA-LDL antibodies are not well understood. Furthermore, it is not known whetherthese can be modified in patients with coronary artery disease by percutaneouscoronary intervention (PCI).Methods: The Objective Randomised Blinded Investigation with optimal medicalTherapy of Angioplasty in stable angina (ORBITA) trial was the first blinded, multicentre randomised trial of PCI versus placebo procedure for angina relief. Serumsamples were available at four time-points: pre-randomisation pre- (P1) and post- (P2)exercise and post-randomisation (six-weeks following the PCI or placebo procedure),pre- (P3) and post- (P4) exercise. ELISAs were performed using laboratory-developedassays for MDA-LDL (adjusted for Apolipoprotein B) and anti-MDA-LDL antibodies.Results: 196 of the 200 patients (age 66.1 [SD 8.99] years, 28% female) with severesingle vessel coronary artery disease suitable for PCI enrolled in the ORBITA trial hadblood available for analysis. With exercise at pre-randomisation (P2 - P1) there wasno significant change in adjusted MDA-LDL (-0.001, 95% CI -0.004 to 0.001; p=0.287);however, IgG and IgM anti-MDA-LDL significantly declined (-0.022, 95% CI -0.029 to-0.014, p<0.0001; -0.016, 95% CI -0.024 to -0.008, p=0.0002, respectively). PCI didnot have a significant impact on either the pre-exercise values (P3 controlling for P1)of MDA-LDL (p=0.102), IgG (p=0.444) or IgM anti-MDA-LDL(p=0.909). Nor did PCIimpact the exercise induced changes in these markers (P4 controlling for P1, P2, andP3) for MDA-LDL (p=0.605), IgG (p=0.725) or IgM anti-MDA-LDL (p=0.171). Prerandomisation ischaemia on stress echo did not impact these interactions.Conclusions: Exercise results in an acute reduction in anti-oxLDL antibodies inpatients with severe single vessel coronary disease, possibly indicating an inductionin homoeostatic
AU  - Hartley,A
AU  - Khamis,R
AU  - Al-Lamee,R
AU  - Shun-Shin,M
AU  - Haskard,D
AU  - Francis,D
DO  - 10.3389/fcvm.2021.757030
PY  - 2021///
SN  - 2297-055X
TI  - The placebo-controlled effect of percutaneous coronary intervention on exercise induced changes in anti- malondialdehyde-LDL antibody levels in stable coronary artery disease: a substudy of the ORBITA Trial
T2  - Frontiers in Cardiovascular Medicine
UR  - http://dx.doi.org/10.3389/fcvm.2021.757030
UR  - http://hdl.handle.net/10044/1/92261
VL  - 8
ER  -
Download